Because AML samples from patients with concurrent SRSF2 and RUNX1 mutations were resistant to CHK1 inhibition (Figure 2A), we tested whether Runx1 depletion confers CHK1-inhibitor resistance in splicing-factor–mutant mouse hematopoietic progenitors. Here, RUNX1 is linked to acute myeloid leukemia.